{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:17:41Z","timestamp":1783570661310,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82072993, 82222050, 82073003, 82373258 and 82361168664"],"award-info":[{"award-number":["82072993, 82222050, 82073003, 82373258 and 82361168664"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82072993, 82222050, 82073003, 82373258 and 82361168664"],"award-info":[{"award-number":["82072993, 82222050, 82073003, 82373258 and 82361168664"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82072993, 82222050, 82073003, 82373258 and 82361168664"],"award-info":[{"award-number":["82072993, 82222050, 82073003, 82373258 and 82361168664"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Key Research and Development Program of China","award":["2022YFC2505800"],"award-info":[{"award-number":["2022YFC2505800"]}]},{"name":"Medical Scientific Research Foundation of Guangdong Province","award":["B2022184"],"award-info":[{"award-number":["B2022184"]}]},{"DOI":"10.13039\/501100010256","name":"Sci-Tech Project Foundation of Guangzhou City","doi-asserted-by":"crossref","award":["202102020501 and 2024B03J1248"],"award-info":[{"award-number":["202102020501 and 2024B03J1248"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010256","name":"Sci-Tech Project Foundation of Guangzhou City","doi-asserted-by":"crossref","award":["202102020501 and 2024B03J1248"],"award-info":[{"award-number":["202102020501 and 2024B03J1248"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"crossref","award":["2021A1515011139"],"award-info":[{"award-number":["2021A1515011139"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16220-x","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:24:11Z","timestamp":1779805451000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Serum amyloid A kinetics predicts outcomes to PD-1 inhibitors in patients with recurrent or metastatic nasopharyngeal carcinoma"],"prefix":"10.1186","volume":"26","author":[{"given":"Zhiting","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafeng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suchen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamin","family":"chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqing","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenwen","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoxiang","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linquan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"16220_CR1","doi-asserted-by":"publisher","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians. 2021;71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660.","DOI":"10.3322\/caac.21660"},{"key":"16220_CR2","doi-asserted-by":"publisher","unstructured":"Li XY, Luo DH, Guo L, Mo HY, Sun R, Guo SS, Liu LT, Yang ZC, Yang JH, Qiu F et al. Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2022;40(11):1163\u20131173. https:\/\/doi.org\/10.1200\/jco.21.01467.","DOI":"10.1200\/jco.21.01467"},{"key":"16220_CR3","doi-asserted-by":"publisher","unstructured":"Yang Y, Qu S, Li J, Hu C, Xu M, Li W, Zhou T, Shen L, Wu H, Lang J et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. The Lancet Oncology (2021), 22(8):1162\u20131174.https:\/\/doi.org\/10.1016\/s1470-2045(21)00302-8","DOI":"10.1016\/s1470-2045(21)00302-8"},{"key":"16220_CR4","doi-asserted-by":"publisher","unstructured":"Yang Y, Pan J, Wang H, Zhao Y, Qu S, Chen N, Chen X, Sun Y, He X, Hu C et al. Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309). Cancer cell. 2023;41(6):1061\u20131072.e1064. https:\/\/doi.org\/10.1016\/j.ccell.2023.04.014.","DOI":"10.1016\/j.ccell.2023.04.014"},{"key":"16220_CR5","doi-asserted-by":"publisher","unstructured":"Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, Li J, Shi Y, Jin F, Xu R et al. Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial. Jama. 2023;330(20):1961\u20131970. https:\/\/doi.org\/10.1001\/jama.2023.20181.","DOI":"10.1001\/jama.2023.20181"},{"issue":"7","key":"16220_CR6","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1200\/jco.20.02712","volume":"39","author":"FH Wang","year":"2021","unstructured":"Wang FH, Wei XL, Feng J, Li Q, Xu N, Hu XC, Liao W, Jiang Y, Lin XY, Zhang QY, et al. Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02). J Clin oncology: official J Am Soc Clin Oncol. 2021;39(7):704\u201312. https:\/\/doi.org\/10.1200\/jco.20.02712.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"key":"16220_CR7","doi-asserted-by":"publisher","unstructured":"Ma BBY, Lim WT, Goh BC, Hui EP, Lo KW, Pettinger A, Foster NR, Riess JW, Agulnik M, Chang AYC et al. Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2018;36(14):1412\u20131418. https:\/\/doi.org\/10.1200\/jco.2017.77.0388.","DOI":"10.1200\/jco.2017.77.0388"},{"key":"16220_CR8","doi-asserted-by":"publisher","unstructured":"Li SC, Deng SW, Sun XS, Lan KQ, Guo CY, Lin DF, Liu LT, Liu SL, Mai HQ, Tang LQ. A new prognostic model for predicting outcomes of patients with recurrent or metastatic nasopharyngeal carcinoma receiving subsequent line (\u2265\u20092 lines) anti-programmed death-1 monotherapy. Oral oncology. 2023;139:106336. https:\/\/doi.org\/10.1016\/j.oraloncology.2023.106336.","DOI":"10.1016\/j.oraloncology.2023.106336"},{"key":"16220_CR9","doi-asserted-by":"publisher","unstructured":"Liu LT, Tang LQ, Chen QY, Zhang L, Guo SS, Guo L, Mo HY, Zhao C, Guo X, Cao KJ et al. The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma. International journal of radiation oncology, biology, physics. 2015;93(4):862\u2013869. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.08.003.","DOI":"10.1016\/j.ijrobp.2015.08.003"},{"key":"16220_CR10","doi-asserted-by":"publisher","unstructured":"Tang LQ, Li CF, Chen QY, Zhang L, Lai XP, He Y, Xu YX, Hu DP, Wen SH, Peng YT et al. High-sensitivity C-reactive protein complements plasma Epstein-Barr virus deoxyribonucleic acid prognostication in nasopharyngeal carcinoma: a large-scale retrospective and prospective cohort study. International journal of radiation oncology, biology, physics. 2015;91(2):325\u2013336. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.10.005.","DOI":"10.1016\/j.ijrobp.2014.10.005"},{"key":"16220_CR11","doi-asserted-by":"publisher","unstructured":"Xu JY, Wei XL, Ren C, Zhang Y, Hu YF, Li JY, Chen JL, Wang YQ, Han F, Wang FH. Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti-Programmed Cell Death 1 Immunotherapy. JAMA network open. 2022;5(3):e220587. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.0587.","DOI":"10.1001\/jamanetworkopen.2022.0587"},{"key":"16220_CR12","doi-asserted-by":"publisher","unstructured":"Lee AWM, Lee VHF, Ng WT, Strojan P, Saba NF, Rinaldo A, Willems SM, Rodrigo JP, Forastiere AA, Ferlito A. A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma. European journal of cancer (Oxford, England: 1990). 2021;153:109\u2013122. https:\/\/doi.org\/10.1016\/j.ejca.2021.05.022.","DOI":"10.1016\/j.ejca.2021.05.022"},{"key":"16220_CR13","doi-asserted-by":"publisher","unstructured":"Chen QY, Tang QN, Tang LQ, Chen WH, Guo SS, Liu LT, Li CF, Li Y, Liang YJ, Sun XS et al. Pretreatment Serum Amyloid A and C-reactive Protein Comparing with Epstein-Barr Virus DNA as Prognostic Indicators in Patients with Nasopharyngeal Carcinoma: A Prospective Study. Cancer research and treatment. 2018;50(3):701\u2013711. https:\/\/doi.org\/10.4143\/crt.2017.180.","DOI":"10.4143\/crt.2017.180"},{"issue":"1","key":"16220_CR14","doi-asserted-by":"publisher","first-page":"7041","DOI":"10.1038\/s41467-022-34743-2","volume":"13","author":"T Schulte","year":"2022","unstructured":"Schulte T, Chaves-Sanjuan A, Mazzini G, Speranzini V, Lavatelli F, Ferri F, Palizzotto C, Mazza M, Milani P, Nuvolone M, et al. Cryo-EM structure of ex vivo fibrils associated with extreme AA amyloidosis prevalence in a cat shelter. Nat Commun. 2022;13(1):7041. https:\/\/doi.org\/10.1038\/s41467-022-34743-2.","journal-title":"Nat Commun"},{"key":"16220_CR15","doi-asserted-by":"publisher","unstructured":"He RL, Zhou J, Hanson CZ, Chen J, Cheng N, Ye RD. Serum amyloid A induces G-CSF expression and neutrophilia via Toll-like receptor 2. Blood. 2009;113(2):429\u2013437. https:\/\/doi.org\/10.1182\/blood-2008-03-139923.","DOI":"10.1182\/blood-2008-03-139923"},{"key":"16220_CR16","doi-asserted-by":"publisher","unstructured":"Urieli-Shoval S, Linke RP, Matzner Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Current opinion in hematology. 2000;7(1):64\u201369. https:\/\/doi.org\/10.1097\/00062752-200001000-00012.","DOI":"10.1097\/00062752-200001000-00012"},{"issue":"6","key":"16220_CR17","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1007\/s00262-020-02788-1","volume":"70","author":"V Di Noia","year":"2021","unstructured":"Di Noia V, D\u2019Argento E, Pilotto S, Vita E, Ferrara MG, Damiano P, Ribelli M, Cannella A, Virtuoso A, Fattorossi A, et al. Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory FoRECATT study. Cancer Immunol immunotherapy: CII. 2021;70(6):1583\u201392. https:\/\/doi.org\/10.1007\/s00262-020-02788-1.","journal-title":"Cancer Immunol immunotherapy: CII"},{"key":"16220_CR18","doi-asserted-by":"publisher","unstructured":"He LN, Fu S, Zhang X, Hu Q, Du W, Li H, Chen T, Chen C, Jiang Y, Zhou Y et al. Baseline and early changes in circulating Serum Amyloid A (SAA) predict survival outcomes in advanced non-small cell lung cancer patients treated with Anti-PD-1\/PD-L1 monotherapy. Lung cancer (Amsterdam, Netherlands). 2021;158:1\u20138. https:\/\/doi.org\/10.1016\/j.lungcan.2021.05.030.","DOI":"10.1016\/j.lungcan.2021.05.030"},{"issue":"1","key":"16220_CR19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/sj.bjc.6605720","volume":"103","author":"SL Wood","year":"2010","unstructured":"Wood SL, Rogers M, Cairns DA, Paul A, Thompson D, Vasudev NS, Selby PJ, Banks RE. Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer. Br J Cancer. 2010;103(1):101\u201311. https:\/\/doi.org\/10.1038\/sj.bjc.6605720.","journal-title":"Br J Cancer"},{"key":"16220_CR20","doi-asserted-by":"publisher","unstructured":"Cho WC, Yip TT, Cheng WW, Au JS. Serum amyloid A is elevated in the serum of lung cancer patients with poor prognosis. British journal of cancer. 2010; 102(12):1731\u20131735. https:\/\/doi.org\/10.1038\/sj.bjc.6605700.","DOI":"10.1038\/sj.bjc.6605700"},{"issue":"13","key":"16220_CR21","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1200\/jco.2008.18.0554","volume":"27","author":"P Findeisen","year":"2009","unstructured":"Findeisen P, Zapatka M, Peccerella T, Matzk H, Neumaier M, Schadendorf D, Ugurel S. Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling. J Clin oncology: official J Am Soc Clin Oncol. 2009;27(13):2199\u2013208. https:\/\/doi.org\/10.1200\/jco.2008.18.0554.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"key":"16220_CR22","doi-asserted-by":"publisher","unstructured":"Kl\u00fcmper N, Saal J, Berner F, Lichtensteiger C, Wyss N, Heine A, Bauernfeind FG, Ellinger J, Brossart P, Diem S et al. C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer. Journal for immunotherapy of cancer. 2022;10(3):e004024. https:\/\/doi.org\/10.1136\/jitc-2021-004024.","DOI":"10.1136\/jitc-2021-004024"},{"key":"16220_CR23","doi-asserted-by":"publisher","unstructured":"Kl\u00fcmper N, Sikic D, Saal J, B\u00fcttner T, Goldschmidt F, Jarczyk J, Becker P, Zeuschner P, Weinke M, Kalogirou C et al. C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma. European journal of cancer (Oxford, England: 1990). 2022;167:13\u201322. https:\/\/doi.org\/10.1016\/j.ejca.2022.02.022.","DOI":"10.1016\/j.ejca.2022.02.022"},{"key":"16220_CR24","doi-asserted-by":"publisher","unstructured":"Shao JY, Li YH, Gao HY, Wu QL, Cui NJ, Zhang L, Cheng G, Hu LF, Ernberg I, Zeng YX. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A\/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Cancer. 2004;100(6):1162\u20131170. https:\/\/doi.org\/10.1002\/cncr.20099.","DOI":"10.1002\/cncr.20099"},{"key":"16220_CR25","doi-asserted-by":"publisher","unstructured":"Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, Li J, Shi YR, Jin F, Xu R et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nature medicine. 2021;27(9):1536\u20131543. https:\/\/doi.org\/10.1038\/s41591-021-01444-0.","DOI":"10.1038\/s41591-021-01444-0"},{"key":"16220_CR26","doi-asserted-by":"publisher","unstructured":"Janzen E, Mendoza-Ferreira N, Hosseinibarkooie S, Schneider S, Hupperich K, Tschanz T, Grysko V, Riessland M, Hammerschmidt M, Rigo F et al. CHP1 reduction ameliorates spinal muscular atrophy pathology by restoring calcineurin activity and endocytosis. Brain: a journal of neurology. 2018;141(8):2343\u20132361. https:\/\/doi.org\/10.1093\/brain\/awy167","DOI":"10.1093\/brain\/awy167"},{"key":"16220_CR27","doi-asserted-by":"publisher","unstructured":"Liu SL, Li XY, Yang JH, Wen DX, Guo SS, Liu LT, Li YF, Luo MJ, Xie SY, Liang YJ et al. Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial. The Lancet Oncology (2024), 25(12):1563\u20131575.https:\/\/doi.org\/10.1016\/s1470-2045(24)00504-7.","DOI":"10.1016\/s1470-2045(24)00504-7"},{"key":"16220_CR28","doi-asserted-by":"publisher","unstructured":"Zhang Y, Zhang J, Sheng H, Li H, Wang R. Acute phase reactant serum amyloid A in inflammation and other diseases. Advances in clinical chemistry. 2019;90:25\u201380. https:\/\/doi.org\/10.1016\/bs.acc.2019.01.002.","DOI":"10.1016\/bs.acc.2019.01.002"},{"key":"16220_CR29","doi-asserted-by":"publisher","unstructured":"Biaoxue R, Hua L, Wenlong G, Shuanying Y. Increased serum amyloid A as potential diagnostic marker for lung cancer: a meta-analysis based on nine studies. BMC cancer. 2016;16(1):836. https:\/\/doi.org\/10.1186\/s12885-016-2882-0.","DOI":"10.1186\/s12885-016-2882-0"},{"key":"16220_CR30","doi-asserted-by":"publisher","unstructured":"Yang M, Liu F, Higuchi K, Sawashita J, Fu X, Zhang L, Zhang L, Fu L, Tong Z, Higuchi K. Serum amyloid A expression in the breast cancer tissue is associated with poor prognosis. Oncotarget. 2016;7(24):35843\u201335852. https:\/\/doi.org\/10.18632\/oncotarget.8561.","DOI":"10.18632\/oncotarget.8561"},{"key":"16220_CR31","doi-asserted-by":"publisher","unstructured":"Djurec M, Gra\u00f1a O, Lee A, Troul\u00e9 K, Espinet E, Cabras L, Navas C, Blasco MT, Mart\u00edn-D\u00edaz L, Burdiel M et al. Saa3 is a key mediator of the protumorigenic properties of cancer-associated fibroblasts in pancreatic tumors. Proceedings of the National Academy of Sciences of the United States of America. 2018;115(6):E1147-E1156. https:\/\/doi.org\/10.1073\/pnas.1717802115.","DOI":"10.1073\/pnas.1717802115"},{"key":"16220_CR32","doi-asserted-by":"publisher","unstructured":"Ren Y, Wang H, Lu D, Xie X, Chen X, Peng J, Hu Q, Shi G, Liu S. Expression of serum amyloid A in uterine cervical cancer. Diagnostic pathology. 2014;9:16. https:\/\/doi.org\/10.1186\/1746-1596-9-16.","DOI":"10.1186\/1746-1596-9-16"},{"key":"16220_CR33","doi-asserted-by":"publisher","unstructured":"Hansen MT, Forst B, Cremers N, Quagliata L, Ambartsumian N, Grum-Schwensen B, Klingelh\u00f6fer J, Abdul-Al A, Herrmann P, Osterland M et al. A link between inflammation and metastasis: serum amyloid A1 and A3 induce metastasis, and are targets of metastasis-inducing S100A4. Oncogene. 2015;34(4):424\u2013435. https:\/\/doi.org\/10.1038\/onc.2013.568","DOI":"10.1038\/onc.2013.568"},{"key":"16220_CR34","doi-asserted-by":"publisher","unstructured":"Sun L, Zhou H, Zhu Z, Yan Q, Wang L, Liang Q, Ye RD. Ex vivo and in vitro effect of serum amyloid a in the induction of macrophage M2 markers and efferocytosis of apoptotic neutrophils. Journal of immunology (Baltimore, Md: 1950). 2015;194(10):4891\u20134900. https:\/\/doi.org\/10.4049\/jimmunol.1402164.","DOI":"10.4049\/jimmunol.1402164"},{"key":"16220_CR35","doi-asserted-by":"publisher","unstructured":"Hegde PS, Karanikas V, Evers S. The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition. Clinical cancer research: an official journal of the American Association for Cancer Research. 2016;22(8):1865\u20131874. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-1507.","DOI":"10.1158\/1078-0432.Ccr-15-1507"},{"key":"16220_CR36","doi-asserted-by":"publisher","unstructured":"Ozawa Y, Amano Y, Kanata K, Hasegwa H, Matsui T, Kakutani T, Koyauchi T, Tanahashi M, Niwa H, Yokomura K et al. Impact of early inflammatory cytokine elevation after commencement of PD-1 inhibitors to predict efficacy in patients with non-small cell lung cancer. Medical oncology (Northwood, London, England). 2019;36(4):33. https:\/\/doi.org\/10.1007\/s12032-019-1255-3.","DOI":"10.1007\/s12032-019-1255-3"},{"key":"16220_CR37","doi-asserted-by":"publisher","unstructured":"Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nature reviews Drug discovery. 2019;18(3):197\u2013218. https:\/\/doi.org\/10.1038\/s41573-018-0007-y.","DOI":"10.1038\/s41573-018-0007-y"},{"key":"16220_CR38","doi-asserted-by":"publisher","unstructured":"Young LS, Yap LF, Murray PG. Epstein-Barr virus: more than 50 years old and still providing surprises. Nature reviews Cancer. 2016;16(12):789\u2013802. https:\/\/doi.org\/10.1038\/nrc.2016.92.","DOI":"10.1038\/nrc.2016.92"},{"key":"16220_CR39","doi-asserted-by":"publisher","unstructured":"Wang M, Yu F, Wu W, Wang Y, Ding H, Qian L. Epstein-Barr virus-encoded microRNAs as regulators in host immune responses. International journal of biological sciences. 2018;14(5):565\u2013576. https:\/\/doi.org\/10.7150\/ijbs.24562.","DOI":"10.7150\/ijbs.24562"},{"key":"16220_CR40","doi-asserted-by":"publisher","unstructured":"Ressing ME, van Gent M, Gram AM, Hooykaas MJ, Piersma SJ, Wiertz EJ. Immune Evasion by Epstein-Barr Virus. Current topics in microbiology and immunology. 2015;391:355\u2013381. https:\/\/doi.org\/10.1007\/978-3-319-22834-1_12.","DOI":"10.1007\/978-3-319-22834-1_12"},{"key":"16220_CR41","doi-asserted-by":"publisher","unstructured":"Heussinger N, B\u00fcttner M, Ott G, Brachtel E, Pilch BZ, Kremmer E, Niedobitek G. Expression of the Epstein-Barr virus (EBV)-encoded latent membrane protein 2A (LMP2A) in EBV-associated nasopharyngeal carcinoma. The Journal of pathology. 2004;203(2):696\u2013699. https:\/\/doi.org\/10.1002\/path.1569.","DOI":"10.1002\/path.1569"},{"key":"16220_CR42","doi-asserted-by":"publisher","unstructured":"Li J, Lai C, Peng S, Chen H, Zhou L, Chen Y, Chen S. The prognostic value of integration of pretreatment serum amyloid A (SAA)-EBV DNA (S-D) grade in patients with nasopharyngeal carcinoma. Clinical and translational medicine. 2020;9(1):2. https:\/\/doi.org\/10.1186\/s40169-019-0252-7.","DOI":"10.1186\/s40169-019-0252-7"},{"key":"16220_CR43","doi-asserted-by":"publisher","unstructured":"Wang J, Ge J, Wang Y, Xiong F, Guo J, Jiang X, Zhang L, Deng X, Gong Z, Zhang S et al. EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1. Nature communications. 2022;13(1):866. https:\/\/doi.org\/10.1038\/s41467-022-28479-2.","DOI":"10.1038\/s41467-022-28479-2"},{"key":"16220_CR44","doi-asserted-by":"publisher","unstructured":"Ge J, Wang J, Xiong F, Jiang X, Zhu K, Wang Y, Mo Y, Gong Z, Zhang S, He Y et al. Epstein-Barr Virus-Encoded Circular RNA CircBART2.2 Promotes Immune Escape of Nasopharyngeal Carcinoma by Regulating PD-L1. Cancer research. 2021;81(19):5074\u20135088. https:\/\/doi.org\/10.1158\/0008-5472.Can-20-4321.","DOI":"10.1158\/0008-5472.Can-20-4321"},{"key":"16220_CR45","doi-asserted-by":"publisher","unstructured":"Li X, Guo Y, Xiao M, Zhang W. The immune escape mechanism of nasopharyngeal carcinoma. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2023;37(7):e23055. https:\/\/doi.org\/10.1096\/fj.202201628RR.","DOI":"10.1096\/fj.202201628RR"},{"key":"16220_CR46","doi-asserted-by":"publisher","unstructured":"Qiu MZ, Wang C, Wu Z, Zhao Q, Zhao Z, Huang CY, Wu W, Yang LQ, Zhou ZW, Zheng Y et al. Dynamic single-cell mapping unveils Epstein\u2013Barr virus-imprinted T-cell exhaustion and on-treatment response. Signal transduction and targeted therapy. 2023;8(1):370. https:\/\/doi.org\/10.1038\/s41392-023-01622-1.","DOI":"10.1038\/s41392-023-01622-1"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16220-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16220-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16220-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:12:09Z","timestamp":1783570329000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16220-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16220"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16220-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"5 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the Clinical Research Committee of the Sun Yat-Sen University Cancer Center (B2022\u2013497). As a retrospective study, the requirement for informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"831"}}